Biomarker method validation in anticancer drug development
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Over recent years the role of biomarkers in anticancer drug development has expanded across a spectrum of applications ranging from research tool during early discovery to surrogate endpoint in the clinic. However, in Europe when biomarker measurements are performed on samples collected from subjects entered into clinical trials of new investigational agents, laboratories conducting these analyses become subject to the Clinical Trials Regulations. While these regulations are not specific in their requirements of research laboratories, quality assurance and in particular assay validation are essential. This review, therefore, focuses on a discussion of current thinking in biomarker assay validation. Five categories define the majority of biomarker assays from ‘absolute quantitation’ to ‘categorical’. Validation must therefore take account of both the position of the biomarker in the spectrum towards clinical end point and the level of quantitation inherent in the methodology. Biomarker assay validation should be performed ideally in stages on ‘a fit for purpose’ basis avoiding unnecessarily dogmatic adherence to rigid guidelines but with careful monitoring of progress at the end of each stage. These principles are illustrated with two specific examples: (a) absolute quantitation of protein biomarkers by mass spectrometry and (b) the M30 and M65 ELISA assays as surrogate end points of cell death. British Journal of Pharmacology (2008) 153, 646–656; doi:10.1038/sj.bjp.0707441; published online 17 September 2007
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quantitative analysis of complex protein mixtures using isotope-coded affinity tags
Gygi, S. P., Rist, B., Gerber, S. A., Turecek, F., Gelb, M. H., & Aebersold, R. (1999) · Nature Biotechnology · doi:10.1038/13690 · Cited by 4,683 · cited 2×
“, 2002), isotope-coded affinity tags (iCATs; Gygi et al., 1999), incorporation of (18)O into tryptic digests (Yao et al.”
BackgroundMethodRoss, P. L., Huang, Y. N., Marchese, J. N., Williamson, B., Parker, K., Hattan, S., Khainovski, N., Pillai, S., Dey, S., Daniels, S., et al. (2004) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m400129-mcp200 · Cited by 4,401 · cited 2×
“…a quantitative element into proteomics such as metabolic pre-labelling (Gu et al., 2002), isotope-coded affinity tags (iCATs; Gygi et al., 1999), incorporation of 18O into tryptic digests (Yao et al., 2003) and isobaric tags for relative and absolute quantitation (iTRAQ; Ross et al., 2004).”
BackgroundMethodUse of proteomic patterns in serum to identify ovarian cancer
Petricoin, E. F., Ardekani, A. M., Hitt, B. A., Levine, P. J., Fusaro, V. A., Steinberg, S. M., Mills, G. B., Simone, C., Fishman, D. A., Kohn, E. C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07746-2 · Cited by 3,236
Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS
Gerber, S. A., Rush, J., Stemman, O., Kirschner, M. W., & Gygi, S. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0832254100 · Cited by 1,733
Phases of Biomarker Development for Early Detection of Cancer
Pepe, M. S., Etzioni, R., Feng, Z., Potter, J. D., Thompson, M. L., Thornquist, M., Winget, M., & Yasui, Y. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1054 · Cited by 1,686 · cited 1×
“Internationally recognized standards for the various different parameters of bioanalytical method performance have been established (Shah et al., 1991, 2000; Peters et al., 2007).”
BackgroundLesko, L., & Atkinson, A. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.347 · Cited by 465
Cited by
Programmed cell death detection methods: a systematic review and a categorical comparison
Kari, S., Subramanian, K., Altomonte, I. A., Murugesan, A., Yli-Harja, O., & Kandhavelu, M. (2022) · Apoptosis · doi:10.1007/s10495-022-01735-y · Cited by 415
Chunarkar-Patil, P., Kaleem, M., Mishra, R., Ray, S., Ahmad, A., Verma, D., Bhayye, S., Dubey, R., Singh, H., & Kumar, S. (2024) · Biomedicines · doi:10.3390/biomedicines12010201 · Cited by 390
Mollenhauer, B., Cullen, V., Kahn, I., Krastins, B., Outeiro, T. F., Pepivani, I., Ng, J., Schulz-Schaeffer, W., Kretzschmar, H. A., McLean, P. J., et al. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.06.004 · Cited by 382
Sarafian, M. H., Gaudin, M., Lewis, M. R., Martin, F.-P., Holmes, E., Nicholson, J. K., & Dumas, M.-E. (2014) · Analytical Chemistry · doi:10.1021/ac500317c · Cited by 301
Chowdhury, F., Williams, A., & Johnson, P. (2009) · Journal of Immunological Methods · doi:10.1016/j.jim.2008.10.002 · Cited by 284
Metadata
- Authors
- Cummings, J., Ward, T. H., Greystoke, A., Ranson, M., & Dive, C.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2008-02
- Volume
- 153
- Issue
- 4
- Pages
- 646-656
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2135768750
- Cited by
- 131
- References
- 6
- FWCI
- 4.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Biomarker method validation in anticancer drug development. https://app.cochat.ai/papers/10.1038/sj.bjp.0707441
- The paper
- Cummings, J., Ward, T. H., Greystoke, A., Ranson, M., & Dive, C. (2008). Biomarker method validation in anticancer drug development. British Journal of Pharmacology. https://doi.org/10.1038/sj.bjp.0707441
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.